Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment
17 4월 2024 - 9:00PM
Science 37 Holdings, Inc., the clinical research industry’s leading
MetasiteTM, today announced the launch of a stand-alone Patient
Recruitment Solution to deliver patients to sites that are
eligible, medically reviewed, and fully consented.
While traditional central patient recruitment campaigns have
proven to be effective in accelerating enrollment, they are fraught
with inefficiencies. The majority of referred patients are not
fully qualified, do not have a documented medical history, or are
not fully informed regarding expectations for the study. Many sites
don’t have adequate resources to follow up on all their referrals,
and even when they can, very few patients ever make it to their
first screening visit. Sometimes these patient referrals are even
offered the ability to participate in competing studies.
Science 37 is leveraging its Metasite to not only recruit
patients but also to acquire and review the patients’ full medical
records and consent the patients into studies with oversight from
Science 37 Primary Investigators. The Company also has the
capability to manage many of the run-in procedures—from the comfort
of the patient’s own home—that are often required to fully qualify
a participant.
“We’ve been recruiting, qualifying, and consenting patients for
10 years as a Metasite,” said Erica Prowisor, SVP of Patient &
Provider Networks at Science 37. “We empathize with sites on the
complexity required to turn a referral into a consented
participant. Today, we’re offering sponsors the opportunity to
relieve sites of that burden, ensure their recruitment spend is
more efficient, and meet their ultimate goal of accelerated
enrollment.”
With its recent merger with eMed, Science 37 will dramatically
expand its access to new patients and technology to further enhance
its enrollment process. The Company also has a patent pending with
respect to its solution to ensure it will continue to be
one-of-a-kind.
About eMed
eMed is a telehealth and diagnostics company that develops a
leading digital point-of-care platform designed for complete
testing processes to be done at home. The company's platform
provides verified test results and access to on-demand prescription
treatment with same-day delivery, enabling consumers to easily get
tested and receive expert healthcare guidance.
About Science 37
Science 37’s mission is to accelerate clinical research by
enabling universal trial access for patients. Through our
solutions; The Metasite™ and Patient Recruitment, we accelerate
enrollment by expanding the reach of clinical trials to patients
beyond the traditional site and rigorously qualifying patients
prior to referring them to a traditional site. Our solutions are
powered by a proprietary technology stack with in-house medical and
operational experts that enhance quality through standardized
workflows and best-in-class study orchestration. To learn more,
visit www.science37.com, or email science37@science37.com.
To view studies that Science 37 is actively recruiting for,
please visit https://studies.science37.com/current-studies/.
Media Inquiries
Science 37pr@science37.com
Science 37 (NASDAQ:SNCE)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Science 37 (NASDAQ:SNCE)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025